Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated October 29, 2026, announcing the financial results of Eli Lilly and Company for the quarter ended September 30, 2026.
|
Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and markets human pharmaceutical products. Incorporated in 1901 to succeed a drug manufacturing business founded in 1876, the company operates in a single business segment. Its product portfolio is organized into four therapeutic areas: cardiometabolic health, oncology, immunology, and neuroscience. Key products include Mounjaro and Zepbound for diabetes and obesity, Jardiance and Trulicity for cardiometabolic conditions, and Humalog and Humulin for insulin therapy. In oncology, the company markets Cyramza, Erbitux, Retevmo, and Verzenio. Immunology products include Taltz, Olumiant, and Omvoh, while neuroscience offerings feature Emgality and Kisunla. The company collaborates with partners such as Boehringer Ingelheim, Incyte Corporation, Innovent Biologics, and Almirall S.A. for specific products. Eli Lilly manufactures and distributes its medicines through facilities in the United States, Europe, and Asia, selling in multiple countries. In the U.S., distribution is primarily through wholesalers, and the company utilizes LillyDirect, a direct-to-patient digital healthcare platform, for medicine delivery and patient support. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Drug Manufacturers - General | Homepage lilly.com |
| Sector Healthcare | IR page lilly.com | |
|
Tags
cardiometabolic health, oncology, immunology, neuroscience, diabetes, obesity, insulin, glp-1 receptor agonists, sglt2 inhibitors, cancer therapy, autoimmune diseases, alzheimer's disease, Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity, Zepbound, Cyramza, Erbitux, Inluriyo, Jaypirca, Retevmo, Tyvyt, Verzenio, Ebglyss, Olumiant, Omvoh, Taltz, Emgality, Kisunla, LillyDirect
|
Press page lilly.com/jp/news/stories |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 1.319T |
| Market cap (USD) | $ 1.319T |
| P/E | 45.52 |
| PEG | 0.93 |
| P/BV | 32.76 |
| P/S | 15.26 |
| P/OCF | 43.06 |
| P/FCF | 221.23 |
| Dividend yield | 0.44% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 101.4% |
| ROI | 29.9% |
| ROIC | 34.5% |
| Profit margin | 31.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 49.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 122.9% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 24 |
| Quality score | 36.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.179B | 45.043B | 34.124B | 28.541B | 28.318B | 24.54B | 22.32B | 24.556B | 22.871B | 21.222B | 19.959B | 19.616B | 23.113B | 22.603B | 24.287B | 23.076B | 21.836B | 20.378B | 18.634B | 15.691B | 14.645B | 13.858B | 12.583B | 11.078B | 11.543B | — |
| Net profit | 20.64B | 10.59B | 5.24B | 6.245B | 5.582B | 6.194B | 8.318B | 3.232B | -204.1M | 2.738B | 2.408B | 2.391B | 4.685B | 4.089B | 4.348B | 5.07B | 4.329B | -2.072B | 2.953B | 2.663B | 1.98B | 1.81B | 2.561B | 2.708B | — | 3.058B |
| Free cash flow | 5.964B | 414M | -3.152B | 4.6B | 5.388B | — | — | — | — | — | — | — | — | — | — | — | — | 6.348B | 4.072B | 2.898B | 615.5M | 971.4M | 1.94B | 939.8M | 2.778B | 3.054B |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 1.075K | 772 | 582.92 | 365.84 | 276.22 | 168.84 | 131.43 | 115.72 | 84.46 | 73.55 | 84.26 | 68.99 | 51 | 49.32 | 41.56 | 35.04 | 35.71 | 40.27 | 57.35 | 54.12 | — | — | — | — | — | — |
| Price performance 12m | 0.39 | 0.32 | 0.59 | 0.32 | 0.64 | 0.28 | 0.14 | 0.37 | 0.15 | -0.13 | 0.22 | 0.35 | 0.03 | 0.19 | 0.19 | -0.02 | -0.11 | -0.3 | 0.06 | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 4.03B | 4.55B | 5.25B | 4.55B | 5.88B | 6.67B | 6.9B | 9.09B | 11B | 17.8B |
| ↳ YoY growth | +14.7% | +12.8% | +15.4% | -13.3% | +29.2% | +13.6% | +3.3% | +31.8% | +21.1% | +61.4% |
| ↳ 5y CAGR | +2.3% | +6.4% | +8.8% | +7.0% | +10.8% | +10.6% | +8.7% | +11.6% | +19.3% | +24.8% |
| Borrowings, current (USD) | 1.3B | 2.7B | 499M | 1.49B | 0.00 | 1.54B | 1.5B | 6.19B | 4.34B | 0.00 |
| Borrowings, non-current (USD) | 8.37B | 9.94B | 11.6B | 13.8B | 16.6B | 15.3B | 14.7B | 18.3B | 28.5B | 40.9B |
| Lease liabilities (USD) | — | — | 595M | 487M | 664M | 686M | 728M | 1.11B | 1.15B | 1.36B |
| Cash and deposits (USD) | 4.58B | 6.54B | 8B | 2.34B | 3.66B | 3.82B | 2.07B | 2.82B | 3.27B | 7.27B |
| Intangible assets (USD) | 4.36B | 4.03B | 3.52B | 6.62B | 7.45B | 7.69B | 7.21B | 6.91B | 6.17B | 6.52B |
| Right-of-use assets (USD) | — | — | 530M | 532M | — | — | — | 1.02B | 1.05B | 1.26B |
| Net debt (borrowings + leases - cash) (USD) | 5.09B | 6.1B | 4.14B | 13.5B | 13.6B | 13.8B | 14.9B | 22.8B | 30.7B | 35B |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | 4.85B | 5.62B | 5.52B | 4.84B | 6.5B | 7.26B | 7.08B | 4.24B | 8.82B | 16.8B |
| Purchases of intangible assets (USD) | 0.00 | — | -1.98B | -240M | -660M | -875M | — | — | — | — |
| Change in inventories (cash effect) (USD) | -328M | -254M | 7.8M | -259M | -533M | -236M | -600M | -1.43B | -2.51B | -4.67B |
| Change in payables (cash effect) (USD) | 819M | 916M | -285M | -478M | 1.27B | -664M | 1.33B | 4.27B | 2.61B | 10.2B |
| Dividends paid (cash effect) (USD) | -2.16B | -2.19B | -2.31B | -2.41B | -2.69B | -3.09B | -3.54B | -4.07B | -4.68B | -5.38B |
| Share buybacks (cash effect) (USD) | -600M | -300M | -4.15B | -4.4B | -500M | -1.25B | -1.5B | -750M | -2.5B | -4.11B |
| Interest paid (cash effect) (USD) | -146M | -193M | -224M | -306M | -346M | -338M | -324M | -404M | -578M | -633M |
| Income taxes paid (cash effect) (USD) | -701M | -247M | -1.1B | -1.18B | -955M | -1.6B | -2.67B | -5.56B | -6.56B | -10.8B |
| Share-based compensation (USD) | 255M | 281M | 280M | 312M | 308M | 343M | 371M | 629M | 646M | 626M |
| Income detail | ||||||||||
| Research and development expense (USD) | 5.24B | 5.28B | 5.31B | 5.6B | 6.09B | 7.03B | 7.19B | 9.31B | 11B | 13.3B |
| ↳ 5y CAGR | +0.9% | +0.0% | -0.8% | +3.4% | +4.9% | +6.0% | +6.4% | +11.9% | +14.5% | +17.0% |
| Total comprehensive income (USD) | 2.09B | -29.6M | 3.32B | 7.54B | 6.22B | 7.74B | 6.74B | 4.76B | 10.6B | 22.1B |
| Comprehensive income to owners (USD) | 2.09B | — | — | — | 6.22B | 7.74B | 6.74B | 4.76B | 10.6B | 22.1B |
| Reported | Feb 21, 2017 | Feb 20, 2018 | Feb 17, 2021 | Feb 17, 2021 | Feb 22, 2023 | Feb 22, 2023 | Feb 22, 2023 | Feb 19, 2025 | Feb 19, 2025 | Feb 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR.
Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 5, 2026, announcing the financial results of Eli Lilly and Company for the quarter ended June 30, 2026.
On May 20, 2026, Eli Lilly and Company (the “Company”) completed its offering of $750,000,000 aggregate principal amount of its Floating Rate Notes due 2028 (the “2028 Floating Rate Notes”), $500,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “2029 Floating Rate Notes” and, together with the 2028 Floating Rate Notes, the “Floating Rate Notes”), $750,000,000 aggregate principal amount of its 4.150% Notes due 2029 (the “2029 Notes”), $1,500,000,000 aggregate principal amount of its 4.375% Notes due 2031 (the “2031 Notes”), $1,250,000,000 aggregate principal amount of its 4.650% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of its 4.850% Notes due 2036 (the “2036 Notes”), $1,750,000,000 aggregate principal amount of its 5.600% Notes due 2056 (the “2056 Notes”) and $1,000,000,000 aggregate principal amount of its 5.700% Notes due 2066 (the “2066 Notes” and, collectively with the 2029 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2056 Notes, the “Fixed Rate Notes,” and together with the Floating Rate Notes, the “Notes”).
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Oct 28, 2019 | Renamed | LILLY ELI & CO → ELI LILLY & CO |
ETFs Holding Eli Lilly and Company
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| MEDI | 21.10% | 6,543 | $ 9.327M | Nov 12, 2026 |
| OZEM | 20.49% | 8,083 | $ 11.442M | Nov 17, 2026 |
| MEDX | 18.46% | 2,936 | $ 3.522M | Jun 30, 2026 |
| TMED | 16.71% | 3,209 | $ 3.849M | Jun 30, 2026 |
| GDOC | 12.19% | 2,066 | $ 2.39M | Aug 31, 2026 |
| HRTS | 11.11% | 5,343 | $ 6.18M | Aug 31, 2026 |
| JDOC | 8.78% | 613 | $ 867.732K | Nov 17, 2026 |
| GK | 8.75% | 1,727 | $ 2.445M | Nov 17, 2026 |
| PCLG | 6.99% | 5,045 | $ 5.796M | Jul 31, 2026 |
| VNSE | 6.99% | 823 | $ 987.131K | Jun 30, 2026 |
| PSIL | 6.91% | 1,860 | $ 2.633M | Nov 17, 2026 |
| DUNK | 6.56% | 7,596 | $ 10.875M | Nov 17, 2026 |
| EASY | 5.92% | 3,134 | $ 3.6M | Jul 31, 2026 |
| PJFG | 5.69% | 5,187 | $ 7.342M | Nov 18, 2026 |
| PINK | 5.59% | 13,210 | $ 18.699M | Nov 17, 2026 |
| HFGO | 5.50% | 6,088 | $ 0.00 | Nov 18, 2026 |
| CARK | 5.46% | 15,162 | $ 17.419M | Jul 31, 2026 |
| VGRO | 5.39% | 176 | $ 202.196K | Jul 31, 2026 |
| DUHP | 5.38% | 735,353 | $ 1.05B | Nov 12, 2026 |
| GDIV | 5.20% | 8,721 | $ 12.589M | Nov 13, 2026 |
| CANC | 5.15% | 9,404 | $ 10.878M | Aug 31, 2026 |
| ARKG | 5.04% | 64,741 | $ 91.644M | Nov 18, 2026 |
| EGGY | 5.00% | 4,256 | $ 6.093M | Nov 17, 2026 |
| SXQG | 4.97% | 2,079 | $ 2.964M | Nov 12, 2026 |
| PCGG | 4.97% | 238 | $ 285.464K | Jun 30, 2026 |
| SEMG | 4.94% | 2,146 | $ 3.04M | Nov 18, 2026 |
| FCTE | 4.93% | 10,050 | $ 12.054M | Jun 30, 2026 |
| LOGO | 4.81% | 1,070 | $ 1.532M | Nov 17, 2026 |
| WINN | 4.80% | 39,581 | $ 57.135M | Nov 13, 2026 |
| FRIZ | 4.66% | 204 | $ 244.684K | Jun 30, 2026 |
| FMKT | 4.63% | 318 | $ 455.271K | Nov 17, 2026 |
| BKCG | 4.61% | 4,808 | $ 5.524M | Jul 31, 2026 |
| JGRW | 4.58% | 3,477 | $ 4.022M | Aug 31, 2026 |
| PGRO | 4.56% | 8,361 | $ 9.671M | Aug 31, 2026 |
| USSE | 4.52% | 13,511 | $ 16.205M | Jun 30, 2026 |
| BRIF | 4.43% | 5,703 | $ 6.84M | Jun 30, 2026 |
| BAMG | 4.40% | 4,871 | $ 5.634M | Aug 31, 2026 |
| CAPE | 4.38% | 8,716 | $ 10.454M | Jun 30, 2026 |
| EGGQ | 4.37% | 1,796 | $ 2.571M | Nov 17, 2026 |
| BGRO | 4.32% | 264 | $ 377.961K | Nov 16, 2026 |
| ILDR | 4.29% | 9,515 | $ 13.622M | Nov 16, 2026 |
| RILA | 4.27% | 1,568 | $ 1.801M | Jul 31, 2026 |
| GGRW | 4.23% | 309 | $ 370.624K | Jun 30, 2026 |
| BWTG | 4.08% | 727 | $ 840.943K | Aug 31, 2026 |
| AVIE | 4.06% | 472 | $ 675.748K | Nov 16, 2026 |
| CGUS | 4.00% | 336,007 | $ 481.051M | Nov 16, 2026 |
| GFGF | 3.95% | 1,128 | $ 1.305M | Aug 31, 2026 |
| NUGO | 3.95% | 83,920 | $ 96.411M | Jul 31, 2026 |
| AFOS | 3.90% | 7,574 | $ 10.72M | Nov 18, 2026 |
| SCLZ | 3.88% | 635 | $ 761.638K | Jun 30, 2026 |
| VSLU | 3.69% | 16,801 | $ 20.152M | Jun 30, 2026 |
| TGRT | 3.64% | 40,817 | $ 58.436M | Nov 17, 2026 |
| PJFV | 3.63% | 6,847 | $ 9.692M | Nov 18, 2026 |
| CLCG | 3.59% | 884 | $ 1.016M | Jul 31, 2026 |
| REGS | 3.58% | 1,936 | $ 2.322M | Jun 30, 2026 |
| GROZ | 3.54% | 3,532 | $ 4.086M | Aug 31, 2026 |
| JXX | 3.51% | 815 | $ 936.305K | Jul 31, 2026 |
| WLTG | 3.50% | 2,343 | $ 2.692M | Jul 31, 2026 |
| QDVO | 3.49% | 21,500 | $ 25.788M | Jun 30, 2026 |
| SGRT | 3.46% | 1,314 | $ 1.881M | Nov 17, 2026 |
| HBTA | 3.44% | 7,343 | $ 8.494M | Aug 31, 2026 |
| RSMV | 3.42% | 704 | $ 844.399K | Jun 30, 2026 |
| NANC | 3.35% | 6,334 | $ 9.068M | Nov 17, 2026 |
| FFLG | 3.34% | 17,155 | $ 19.708M | Jul 31, 2026 |
| JGRO | 3.29% | 208,805 | $ 295.574M | Nov 17, 2026 |
| AVUQ | 3.28% | 9,716 | $ 13.91M | Nov 16, 2026 |
| BIGY | 3.28% | 642 | $ 919.132K | Nov 17, 2026 |
| CGGR | 3.26% | 572,848 | $ 820.129M | Nov 16, 2026 |
| BCGD | 3.17% | 258 | $ 309.453K | Jun 30, 2026 |
| NQLT | 3.14% | 1,328 | $ 1.536M | Aug 31, 2026 |
| LOTI | 3.08% | 1,260 | $ 1.448M | Jul 31, 2026 |
| CGCV | 3.08% | 52,881 | $ 75.708M | Nov 16, 2026 |
| SAWG | 3.03% | 76 | $ 87.312K | Jul 31, 2026 |
| HGRO | 3.01% | 3,308 | $ 3.8M | Jul 31, 2026 |
| NBGX | 2.97% | 382 | $ 441.871K | Aug 31, 2026 |
| BBLU | 2.97% | 10,352 | $ 14.65M | Nov 18, 2026 |
| ABFL | 2.96% | 13,534 | $ 15.548M | Jul 31, 2026 |
| HELX | 2.95% | 688 | $ 825.208K | Jun 30, 2026 |
| BDIV | 2.93% | 170 | $ 195.303K | Jul 31, 2026 |
| SPCT | 2.88% | 1,685 | $ 1.936M | Jul 31, 2026 |
| GPT | 2.83% | 559 | $ 670.481K | Jun 30, 2026 |
| XMAG | 2.79% | 4,219 | $ 6.014M | Nov 13, 2026 |
| ESLG | 2.77% | 560 | $ 643.35K | Jul 31, 2026 |
| CCOR | 2.75% | 668 | $ 767.425K | Jul 31, 2026 |
| ACGR | 2.75% | 249 | $ 288.026K | Aug 31, 2026 |
| ZECP | 2.72% | 8,848 | $ 10.235M | Aug 31, 2026 |
| FBCG | 2.71% | 163,157 | $ 187.441M | Jul 31, 2026 |
| FDG | 2.68% | 9,725 | $ 11.249M | Aug 31, 2026 |
| MPLY | 2.61% | 361 | $ 414.731K | Jul 31, 2026 |
| ALRG | 2.55% | 186 | $ 213.684K | Jul 31, 2026 |
| SPIN | 2.55% | 793 | $ 1.135M | Nov 16, 2026 |
| DARP | 2.53% | 485 | $ 694.36K | Nov 17, 2026 |
| QLTY | 2.53% | 113,212 | $ 130.956M | Aug 31, 2026 |
| USMC | 2.53% | 73,514 | $ 88.175M | Jun 30, 2026 |
| LCAP | 2.52% | 38,404 | $ 46.063M | Jun 30, 2026 |
| FELG | 2.52% | 118,478 | $ 142.106M | Jun 30, 2026 |
| SAMM | 2.45% | 621 | $ 744.846K | Jun 30, 2026 |
| SAMT | 2.42% | 17,684 | $ 21.211M | Jun 30, 2026 |
| SMRI | 2.37% | 11,648 | $ 16.49M | Nov 18, 2026 |
| INFO | 2.30% | 15,275 | $ 22.049M | Nov 13, 2026 |